Boehringer acquires ICD to ease biologic delivery

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Natee Meepian)
(Image: Getty/Natee Meepian)

Related tags: Biologics, Drug delivery, Drug delivery systems, Oncology, Boehringer ingelheim, Boehringer

Boehringer acquires rights to ICD Therapeutics and its biologics-delivery platform for the development of oncology and immune oncology compounds.

Using the acquired platform, Boehringer Ingelheim will work with nanoPET Pharma GmbH, a former shareholder of ICD Therapeutics, to develop drug candidates for intracellular targets across tumors.

Boehringer told us that while it has a robust pipeline of oncology and immune oncology compounds in various stages of development, many of its compounds have intracellular targets thus requiring specialized delivery technology, as they are macromolecules.

Per the acquisition, Boehringer will use ICD’s MacroDel technology which enables the exploitation of transporter proteins in the cell membrane to deliver drug candidates inside tumor cells. With this type of drug delivery, Boehringer will have the capability of developing therapeutic targets that would previously been inaccessible, which could be particularly beneficial to patients who have no or only limited treatment options.

Norbert Kraut, global head of cancer research at Boehringer, said in a statement that with the acquired platform from ICD the collaboration with nanoPET Pharma GmbH “has the potential to eliminate the hurdle that many cancer biologics face: getting access to targets inside tumor cells.”

Previous to the collaboration, ICD Therapeutics was a portfolio company of the Boehringer Ingelheim Venture Fund.

No financial details of the acquisition have been disclosed.

Related news

Show more

Related products

show more

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Follow us

Products

View more

Webinars